A revolutionary new perception on anticoagulation treatment in patients with ACS undergoing PCI with DES. New insights that will most probably impact the upcoming guidelines
Most viewed in the last 7 days from JAMA Cardiology: In patients with ACS undergoing percutaneous coronary intervention with drug-eluting stents, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE. https://ja.ma/4iNmbpD
Most viewed in the last 7 days from JAMA Cardiology: In patients with ACS undergoing percutaneous coronary intervention with drug-eluting stents, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE. https://ja.ma/3ZIKU61
Most viewed in the last 7 days from JAMA Cardiology: In patients with ACS undergoing percutaneous coronary intervention with drug-eluting stents, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE. https://ja.ma/4iNmbpD
Most viewed in the last 7 days from JAMA Cardiology: The beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent for patients who experienced percutaneous coronary intervention and were event-free during 6 to 18 months of dual antiplatelet therapy. https://ja.ma/49rxMqr
Most viewed in the last 7 days from JAMA Cardiology: The beneficial impact of clopidogrel monotherapy over aspirin monotherapy was consistent for patients who experienced percutaneous coronary intervention and were event-free during 6 to 18 months of dual antiplatelet therapy. https://ja.ma/4gmoGgD
Most viewed in the last 7 days from JAMA Cardiology: What is the optimal duration of dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention with drug-eluting stents? https://ja.ma/4frqg0z
Most viewed in the last 7 days from JAMA Cardiology: What is the optimal duration of dual antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention with drug-eluting stents? https://ja.ma/3A3usEs
General Manager - Operations at Sakra World Hospital JV by SECOM & TOYOTA TSUSHO, JAPAN / Views are Personal.
Dr. Ashok Kumar’s insights on Hypertension will give you a chance to understand this topic in depth and will surely benefit you in your overall health scenario. Watch out this session 👇
Start your day with vital insights on Hypertension! Tune in for an exclusive chat with Dr. Ashok Kumar, Senior Consultant in Interventional Cardiology at Sakra Institute of Cardiac Sciences. Catch the episode with RJ Manasa on April 24th, 2024, from 8 AM-9 AM. Learn how to manage and treat hypertension effectively. 📞 For more details, call 080 4969 4969 or 1800 202 4969. Visit us at www.sakraworldhospital.com. #sakraworldhospital #multispecialityhospitalinbangalore #hypertension #interventionalcardiology #cardiacsciences
Most viewed in the last 7 days from JAMA Cardiology: This narrative review analyzes associations among heart failure, aortic stenosis, and aortic valve replacement. https://ja.ma/3Up5Dd7
Most viewed in the last 7 days from JAMA Cardiology: This narrative review analyzes associations among heart failure, aortic stenosis, and aortic valve replacement. https://ja.ma/3A1GNt3
A diagnosis of left bundle branch block (LBBB) is hugely impactful for clinical treatment decisions, so it is very important to differentiate from general intraventricular conduction delay/block and/or left ventricular hypertrophy. This paper (https://lnkd.in/gd7r52ZZ) assesses the impact of two sets of LBBB criteria from the European Society of Cardiology (ESC). It is interesting to consider that criteria can be more or less strict and demanding, corresponding to different operating points on a ROC curve. And that the two sets can lead to significant discordance in assessment. It is clear that the 2013 criteria have much higher sensitivity. Figure 1 from the paper is outstanding in demonstrating the effect of individual criteria of varying strictness, as well as the specific LBBB morphologies that are effected. The 2021 criteria appear to reach only 30% of the 2013 criteria sensitivity. Which set of criteria is "better", and in general how to choose an optimal operating point? Depends on the endpoint and clinical implications. It does seem like the loss of sensitivity here is very large, and indeed the new criteria seem unnecessarily highly specific. It is worth noting however that Positive Predictive Value (PPV) is often under-appreciated. A model with high PPV will earn a clinician's trust, and they will be empowered to make treatment decisions more confidently. A Data Scientist will often choose the optimal balance between sensitivity and PPV, but that is too simplistic and naïve. Complicating this discussion is the distinction between interpreting a LBBB pattern on an ECG, and detecting a "true" LBBB with implications for Cardiac Resynchronization Therapy fitness (see https://lnkd.in/gAiqQzBa). Epistemological limit, we're bumping into you again!
